|
Name |
Hexadecanamide
|
Molecular Formula | C16H33NO | |
IUPAC Name* |
hexadecanamide
|
|
SMILES |
CCCCCCCCCCCCCCCC(=O)N
|
|
InChI |
InChI=1S/C16H33NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H2,17,18)
|
|
InChIKey |
HSEMFIZWXHQJAE-UHFFFAOYSA-N
|
|
Synonyms |
Hexadecanamide; Palmitamide; 629-54-9; Palmitic amide; Cetyl amide; Palmitic acid amide; n-Hexadecanamide; Palmityl amide; Amide 16; Amide HPL; CHEBI:74475; Hexadecanoic acid amide; NSC 3327; QX1MQ82M73; NSC-3327; UNII-QX1MQ82M73; EINECS 211-095-5; PALMITAMIDE [INCI]; SCHEMBL43384; CHEMBL32605; palmitamide (ACD/Name 4.0); 2,6-Dichloro-4-nitropyridine?; DTXSID8044707; SCHEMBL23571900; NSC3327; ZINC8689949; BDBM50463964; LMFA08010009; MFCD00025534; AKOS015839800; NCGC00161182-02; PALMITAMIDE (PALMITIC ACID AMIDE); AS-56522; DB-054345; CS-0081845; FT-0626967; H0067; Q18651888
|
|
CAS | 629-54-9 | |
PubChem CID | 69421 | |
ChEMBL ID | CHEMBL32605 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 255.44 | ALogp: | 5.7 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 14 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 43.1 | Aromatic Rings: | 0 |
Heavy Atoms: | 18 | QED Weighted: | 0.42 |
Caco-2 Permeability: | -4.82 | MDCK Permeability: | 0.00002060 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.682 |
30% Bioavailability (F30%): | 0.994 |
Blood-Brain-Barrier Penetration (BBB): | 0.687 | Plasma Protein Binding (PPB): | 97.62% |
Volume Distribution (VD): | 1.021 | Fu: | 1.32% |
CYP1A2-inhibitor: | 0.432 | CYP1A2-substrate: | 0.205 |
CYP2C19-inhibitor: | 0.428 | CYP2C19-substrate: | 0.057 |
CYP2C9-inhibitor: | 0.179 | CYP2C9-substrate: | 0.899 |
CYP2D6-inhibitor: | 0.042 | CYP2D6-substrate: | 0.074 |
CYP3A4-inhibitor: | 0.227 | CYP3A4-substrate: | 0.038 |
Clearance (CL): | 4.583 | Half-life (T1/2): | 0.113 |
hERG Blockers: | 0.332 | Human Hepatotoxicity (H-HT): | 0.022 |
Drug-inuced Liver Injury (DILI): | 0.053 | AMES Toxicity: | 0.009 |
Rat Oral Acute Toxicity: | 0.017 | Maximum Recommended Daily Dose: | 0.012 |
Skin Sensitization: | 0.925 | Carcinogencity: | 0.052 |
Eye Corrosion: | 0.174 | Eye Irritation: | 0.931 |
Respiratory Toxicity: | 0.164 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000608 | 0.895 | D07ILQ | 0.708 | ||||
ENC000050 | 0.821 | D0Z5SM | 0.591 | ||||
ENC000356 | 0.780 | D0O1PH | 0.539 | ||||
ENC000271 | 0.780 | D00AOJ | 0.532 | ||||
ENC000466 | 0.768 | D05ATI | 0.508 | ||||
ENC000472 | 0.765 | D00FGR | 0.500 | ||||
ENC000496 | 0.742 | D0P1RL | 0.402 | ||||
ENC000419 | 0.742 | D0XN8C | 0.392 | ||||
ENC000110 | 0.742 | D00STJ | 0.387 | ||||
ENC001710 | 0.739 | D0T9TJ | 0.367 |